SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-267745
Filing Date
2023-11-01
Accepted
2023-11-01 07:59:53
Documents
16
Period of Report
2023-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d282676d8k.htm   iXBRL 8-K 30531
2 EX-1.1 d282676dex11.htm EX-1.1 191875
3 EX-5.1 d282676dex51.htm EX-5.1 12130
7 GRAPHIC g282676g1031055703195.jpg GRAPHIC 1649
8 GRAPHIC g282676g1031062438179.jpg GRAPHIC 6662
  Complete submission text file 0001193125-23-267745.txt   422028

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apls-20231031.xsd EX-101.SCH 2851
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20231031_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20231031_pre.xml EX-101.PRE 10813
10 EXTRACTED XBRL INSTANCE DOCUMENT d282676d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 231366619
SIC: 2834 Pharmaceutical Preparations